Takemoto Seiji, Nishikawa Makiya, Otsuki Takayuki, Yamaoka Ayumi, Maeda Kazuki, Ota Atsushi, Takakura Yoshinobu
Department of Biopharmaceutics and Drug Metabolism, Graduate School of Pharmaceutical Science, Kyoto University, Sakyo-ku, Kyoto, Sakyo-ku, Japan.
J Control Release. 2009 Apr 2;135(1):11-8. doi: 10.1016/j.jconrel.2008.11.024. Epub 2008 Dec 3.
Heat shock protein 70 (Hsp70)-associated antigens in a soluble form have been shown to elicit strong antigen-specific cytotoxic T lymphocyte (CTL) responses following immunization without any adjuvants. In order to improve the potential of Hsp70, we genetically designed a novel Hsp70-based antigen delivery system, in which the model MHC class I epitope of ovalbumin (OVA) (SIINFEKL; OVA257-264) was fused to mouse Hsp70. To facilitate the cytosolic delivery of the peptide following Hsp receptor-mediated endocytosis, polyhistidine of 25 or 50 residues was further fused to the fusion protein. Each fusion protein was then expressed in E. coli and purified. When added to DC2.4 cells, a mouse dendritic cell line, the fusion protein containing polyhistidine of 25 residues was efficiently taken up by the cells and efficiently distributed to the cytosol. The fusion protein also exhibited a significantly improved efficacy of MHC class I-restricted presentation of antigen. Vaccination of mice with the polyhistidine fusion protein generated strong antigen-specific CTL responses and antitumor activity. These findings suggest that polyhistidine fusion is a useful strategy to increase the potential of Hsp-based vaccination.
可溶性热休克蛋白70(Hsp70)相关抗原已被证明在无任何佐剂的免疫接种后能引发强烈的抗原特异性细胞毒性T淋巴细胞(CTL)反应。为了提高Hsp70的潜力,我们通过基因设计了一种新型的基于Hsp70的抗原递送系统,其中卵清蛋白(OVA)的模型MHC I类表位(SIINFEKL;OVA257 - 264)与小鼠Hsp70融合。为了促进Hsp受体介导的内吞作用后肽的胞质递送,将25或50个残基的多聚组氨酸进一步与融合蛋白融合。然后每种融合蛋白在大肠杆菌中表达并纯化。当添加到小鼠树突状细胞系DC2.4细胞中时,含有25个残基多聚组氨酸的融合蛋白被细胞有效摄取并有效分布到胞质溶胶中。该融合蛋白还表现出MHC I类限制的抗原呈递效率显著提高。用多聚组氨酸融合蛋白对小鼠进行疫苗接种产生了强烈的抗原特异性CTL反应和抗肿瘤活性。这些发现表明多聚组氨酸融合是一种提高基于Hsp的疫苗接种潜力的有用策略。